Meditope receives US patent for its monoclonal antibody drug conjugates

Friday, February 28, 2014, 18:00 Hrs  [IST]

Meditope Biosciences, Inc., a biotechnology company developing novel antibody-drug conjugates using its proprietary monoclonal antibody (mAb) technology platform, has received first US patent No. 8,658,774, entitled “Novel Meditopes and Related Meditope-Monoclonal Antibody Delivery Systems, Synthesis and Therapeutic Uses Thereof.” “We view the issuance of this patent, about two years from initial filing, as validation of the novelty of our platform and an important step in our strategy to build and protect a strong and highly differentiated antibody technology,” said Stephanie Hsieh, Meditope’s president and chief executive officer. “Antibody drug conjugates are an area of significant opportunity in drug development and we look forward to leveraging our unique technology to address the industry’s needs.”